Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Forty Seven Inc.
Headquarters: Menlo Park, CA, United States of America
Website: N/A
Year Founded: 2014
Status: Acquired
BioCentury | Feb 14, 2024
Product Development
Clinical report: Data from Gilead, KalVista, Takeda, Synlogic and AN2
What Gilead’s CD47 failure means for the class; KalVista to submit HAE program; Takeda advances narcolepsy therapy; and more
BioCentury | Sep 28, 2023
Deals
Sept. 27 Quick Takes: Roche and Ionis taking another approach to Huntington disease
Plus: Venture financings for Avalyn, Sitryx and Singaporean newco Automera and updates from Biohaven, Ginkgo, Pfizer, Gilead and Gracell
BioCentury | Jul 22, 2023
Deals
July 21 Quick Takes: Gilead drops CD47 lead indication due to futility
Plus: Turnstone shares sag after upsized IPO, Idorsia unveils cost-cutting plan, and updates from ADC, the FTC, TVM, Verrica and more
BioCentury | Jun 7, 2023
Emerging Company Profile
Bitterroot: applying CD47 biology to cardiovascular disease
With IP from Stanford and Gilead, plus $145M from VCs, the cardio-immunology biotech is also aiming to build efficiencies into expensive CV trials
BioCentury | Mar 23, 2023
Product Development
Gilead’s Parsey sees a rising bar for innovation, with positives despite challenges
Gilead CMO expands on his pipeline rationale, biotech challenges and where step changes might come: The BioCentury Show
BioCentury | Feb 3, 2023
Data Byte
Trodelvy label expansion could further boost Gilead cancer sales after $2.1B year
Still dwarfed by antivirals, cell therapy unit is key growth driver as Yescarta crosses blockbuster threshold
BioCentury | Jul 5, 2022
Deals
TeneoBio shareholders gain another exit as AstraZeneca buys spinout
Pharma adds bispecific with purchase of TeneoTwo, bringing more returns to shareholders, including Lightspeed and Sutter Hill
BioCentury | Jul 1, 2022
Finance
After Forty Seven takeout, MacQuitty finding ‘freedom’ with Lightspeed team
Hybrid firm’s ‘leap’ backing Stanford spinout spurred more life sciences deals, with onetime Abingworth partner building team and portfolio
BioCentury | Jun 24, 2022
Emerging Company Profile
DEM BioPharma: exploring ‘don’t eat me’ white space beyond CD47
Backed with $70M, the start-up unites Trillium alumni with academics to discover more phagocytosis targets for cancer
BioCentury | Jun 7, 2022
Data Byte
Top series A rounds of U.S. biotechs year to date
The year has seen 11 U.S. therapeutics developers raise series As of $75M or more, mostly funding new modality platform plays
Items per page:
1 - 10 of 97